Who we are

At Galapagos, we are united around a single purpose: to transform patient outcomes through life-changing science and innovation for more years of life and quality of life.

We are a fully integrated biotechnology company focused on discovering, developing and commercializing innovative medicines. We are committed to improving patients’ lives worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to commercial programs in immunology, oncology, and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is approved and available in Europe and Japan.

Our mission is to accelerate transformational innovation through the relentless pursuit of groundbreaking science, our entrepreneurial spirit and a collaborative mindset.In 2022, we entered the field of oncology, CAR-T, and antibody-therapy research and development through the acquisitions of CellPoint and AboundBio. The transactions provide us with end-to-end capabilities in CAR-T therapy development and offer the potential for a paradigm shift in the space through the implementation of a breakthrough, decentralized point-of-care manufacturing model, and cutting-edge fully human antibody-based capabilities to design next-generation CAR-Ts and biologicals. We employ more than 1,200 employees, with sites in Belgium (headquarters), the Netherlands, France, Germany, Austria, Italy, Spain, the Nordics, Switzerland, the UK and the US.

Employees per site. Source: 2022 Annual Report